A randomised controlled trial of nurse-managed trial conclusion following early phase cancer trial participation by Cox, K et al.
A randomised controlled trial of nurse-managed trial conclusion
following early phase cancer trial participation
K Cox*,1, E Wilson
1, A Arthur
1, R Elkan
1 and S Armstrong
2
1School of Nursing, University of Nottingham, Faculty of Medicine and Health Sciences, University of Nottingham, Nottingham NG7 2UH, UK;
2Trent
Institute for Health Services Research, University of Nottingham, Faculty of Medicine and Health Sciences, University of Nottingham, Nottingham NG7
2UH, UK
The effect of a nurse-managed intervention, for early phase cancer trial participants at trial conclusion, on psychosocial outcomes was
evaluated at two cancer centres in the Midlands, England using a randomised controlled trial. It involved 117 patients who were
participating in an early phase cancer clinical trial. It was a nurse-managed trial exit, which included a trial exit interview, trial feedback
information leaflet and telephone follow-up compared with standard care at trial conclusion. Psychological distress at 1 week and 4–
6 weeks post-trial conclusion, patient’s knowledge and understanding and patient’s satisfaction were assessed. The results showed
there was no significant difference between the two groups regarding scores for anxiety and depression at time one and time two.
There is some suggestion that the intervention reduced anxiety from trial conclusion to follow-up (P¼0.27). Patients in both groups
felt they had contributed to cancer research through trial participation. However, intervention patients were more likely to feel that
they knew how the trial was going (Po0.001), knew how other people in the trial were doing (P¼0.001), had all the feedback they
needed about the trial they took part in (Po0.01) and knew how they would be followed up (P¼0.02). Patient satisfaction with the
intervention was high (median score¼4.5 where 5 is greatest satisfaction). In conclusion, nurse-managed trial conclusion led to
positive outcomes for patients who had recently completed a clinical trial.
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Participation in clinical trials of new anticancer drugs has become
an increasingly common treatment experience of individuals with
cancer. This is due, in part, to an increasing societal demand for
new treatments and the need to test these treatments in a
systematic way (DOH, 1992). However, until recently there has
been relatively little attention paid to the impact of the experience
of clinical trials on those who participate in them (Mackillop and
Johnston, 1986; Gotay, 1991; Kodish et al, 1992). There is evidence
from qualitative research that trial conclusion is the most difficult
time for the subjects of clinical research, who often feel abandoned,
want feedback about the trial they took part in and have unmet
information and psychosocial needs (Cox, 2000).
The management of trial conclusion is a neglected area. Staff
resource in terms of support, time and information is directed at the
stage of trial recruitment and trial participation. However, trials staff
have an ethical responsibility to ensure appropriate support for those
who have been research participants (Harth and Thong, 1995).
One of the ways individuals cope with cancer is that they seek
more information (Weisman, 1979). If information is given
effectively, anxiety and side effects of treatment can be reduced,
enhancing an individuals ability to cope with their illness
(Ridgeway and Matthews, 1982; Slevin et al, 1996). Recognising
and meeting the very specific information and support require-
ments at trial conclusion may be one way that on-going
psychosocial support can be provided to trial patients and enable
them and their families to cope better with trial conclusion. The
study presented in this paper sought to provide an alternative
model of trial conclusion management, which responded to the
issues identified above and establish if this improved the trial
conclusion experience for patients. In this study, trial conclusion is
defined as the point in time when a patient has completed the
planned course of treatment or they were withdrawn due to
unacceptable toxicity or lack of response.
METHODS
The study was conducted in two cancer centres. All patients who
were currently undergoing participation in all the phase I or II
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santicancer drug trials underway in the two centres were invited to
participate via a letter and information sheet given to them by their
trials nurse. Those who agreed provided signed consent. It should
be noted that patients offered phase I and II studies are often at the
end of their disease trajectory and as such the patients in this study
had a limited life expectancy. Ethical approval and NHS Trust
approval was granted at each study site.
Randomisation
A computer-generated list of random codes using block randomi-
sation was generated by SA and held by a research secretary.
Participants to our study were randomly allocated following
recruitment to the study. Each participant had an equal chance of
being allocated to the intervention group (nurse-managed follow-
up) or the control group (standard care).
Intervention
The intervention was developed in the light of findings from our
earlier work (Cox, 2000), discussions with consultant oncologists,
trials nurses and patients and families who were asked if they
would comment on ideas and information sheets. This preliminary
work and the findings from the earlier study indicated that the
intervention would consist of three elements (see Box 1). In
addition to standard care, the trial exit interview and feedback
leaflet were delivered in the week following trial conclusion and the
telephone call was undertaken 2 weeks after trial conclusion.
The trial nurses who were to be involved in delivering the
intervention all underwent a short training session to ensure their
understanding of the process of undertaking the trial exit
interview, how to complete the trial feedback sheets and how to
conduct the telephone interviews. These training sessions were led
by KC and EW and were designed to identify any problems with
the intervention, make sure the documentation was appropriate
and also to ensure that there was a consistency in its implementa-
tion.
Standard care
For patients allocated to standard care, information, support and
follow-up was offered at the end of the drug trial by their trials
doctor and consisted of a consultation that covered details of
reasons for trial conclusion and a monthly follow-up appointment
back at the cancer centre.
Outcome measures
Outcome measures were psychological distress at 1 week and
4–6 weeks post-trial conclusion, patient’s knowledge and under-
standing and patient’s satisfaction. These were recorded either
at the patient’s home or the cancer centre according to
patient preference approximately 7–10 days following trial
conclusion and after the intervention for the intervention group
(time one) and approximately 6 weeks following trial conclusion
(time two).
Time one An evaluation questionnaire was specifically designed
for the study. The questionnaire collected data on patients’
experience of trial conclusion and follow-up, their information
requirements, knowledge and understanding of the trial outcome
and their follow-up care, satisfaction with trial involvement and
their care during the trial and adjustment to no longer being in the
trial. Questions ranged from fixed choice, rating scales and likert
scales to open comments. Patients either self-completed or
completed the form with the researcher according to their personal
preference.
Psychological distress was measured using the Hospital Anxiety
and Depression Scale (HADs) (Zigmond and Snaith, 1983)
generating individual scores for anxiety and depression, both
ranging from 0 to 21 with higher scores indicating a greater degree
of anxiety or depression. Psychological and physical distress was
also measured using the Rotterdam Symptom Checklist (Pruyn
et al, 1980; de Haes et al, 1990). Psychological and physical distress
scores were standardised so they represented a percentage of the
maximum score with higher scores representing greater distress.
Hopwood et al (1991) note that the HADs and the RSCL may
screen out different individuals with affective disorders. With these
factors in mind it was appropriate to use both the RSCL and the
HADs in this study in order to assess psychological distress at trial
conclusion. To assess satisfaction with the intervention patients in
the intervention arm of the study also completed the Medical
Interview Satisfaction Scale (MISS) (Wolf et al, 1978). The tool was
designed to measure satisfaction with medical consultations/
interviews. While this tool is acknowledged as being a relatively
crude measure, as responses on these kinds of scales tend to be
skewed towards the satisfied (Ware and Hays, 1988), it was felt that
it would provide some indication of patient’s satisfaction with the
trial exit interview at data point one which could then be
elaborated on in subsequent interviews at data point two. The
reliability and validity of the tool has not been extensively tested
but Kinnersley et al (1996) noted in a comparison of methods to
measure satisfaction with consultations in primary care that levels
of reliability for the overall scale and subscales was fair to good for
the MISS. The tool was adapted for use in this study to refer to
nurses rather than doctors and has 26 items that measure
satisfaction with the affective, behavioural and cognitive aspects
of medical encounters. The adaptation primarily involved
substituting the word doctor with nurse and substituting reference
to being ill to being in a trial.
Time two Patients completed repeat HADs and RSCL ques-
tionnaires and took part in an in-depth interview (not reported
here) examining patients’ experience of trial conclusion and
follow-up, their knowledge and understanding of the trial out-
come and their follow-up care, satisfaction with trial involvement
and their care during the trial and adjustment to no longer being
in the trial.
Sample size
Based on previous work (Cox, 2000) at the time of trial conclusion,
38% of patients had mild to severe anxiety as assessed by the HAD
scale. It was estimated that through the intervention, this would be
decreased by just over half to 15% at time one (taking into account
reported prevalence rates for anxiety and depression in popula-
tions of cancer patients of around 17% (Derogatis et al, 1983)). The
Box 1 Key components of nurse-managed trial exit intervention
Drug trial exit interview
K Debriefing of decision around completion/withdrawal
K Explanation of further follow-up support
Information leaflet
K A thank you for participating in the trial
K Latest information about the drug being tested
K News about other participants
K Details about the participant’s contribution to cancer research
K Available support after drug trial participation
K Details on further follow-up
Telephone follow-up at 2 weeks postdrug trial exit
K Enquiry as to general health
K Identification of unmet information needs
K Emotional support if required
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(a¼0.05 (two sided) with 80% power, Machin et al, 1997).
Statistical methods
Differences between scores on information received, infor-
mation requirements, knowledge and understanding of the
trial outcome, anxiety and depression, psychological and
physical distress were compared between groups using the
Mann–Whitney U test because the distribution of the scores
was skewed.
RESULTS
Figure 1 reports the flow of participants through the study.
Between 1 January 2001 and 1 February 2004, 129 patients were
approached about participating in the study. A total of 12 chose
not to be involved and the remaining 117 (91%) agreed to be part
of the study providing signed written consent. These were
randomly allocated to either the nurse-led follow-up group
(n¼59) or standard care (n¼58). Measures at time one were
collected on 46 out of 59 of the intervention group and 49 out of 58
of the control group. The main reasons for drop out were refusal,
too ill to participate and death.
Demographic and other characteristics for the two study groups
at drug trial conclusion are reported in Table 1. More men were
included in the study than women, the average age was just under
60 years and the majority was married. Patients were likely to have
one of the common solid tumours. Patients were more likely to
have been withdrawn from the trial in which they were
participating. There was an equal distribution of patients in both
groups across both research sites. There were no obvious
differences between the two groups.
Anxiety and psychological distress
Table 2 presents the HADS median scores for anxiety and
depression and the RSCL median scores for psychological and
physical distress at the two data collection points for both the
intervention and the control groups. The median scores for both
anxiety and depression for these patients over the course of trial
participation were within the normal range for both the HADs (0–
7) (Zigmond and Snaith, 1983). The average scores for psychological
distress for these patients were comparable with those published by
de Haes et al (1990) for patients receiving chemotherapy. There was
no significant difference between the two groups regarding scores
for anxiety and depression, psychological distress or physical
distress at trial conclusion or follow-up. In the intervention group
there was a greater reduction in the anxiety scores from baseline to
follow-up ( 1.2) compared to the control group ( 0.6), although
this was not statistically significant (P¼0.27).
Knowledge and understanding of the trial outcome and
follow-up
Table 3 presents respondents views on information needs and
contribution made to cancer research. There were significant
differences between those in the intervention group when
compared to those in the control group in relation to the
statements; I feel I know how the trial is going (Po0.001), I feel
I know how other people in the trial are doing (P¼0.001), I feel I
Eligible 
(n =129) 
Nurse-managed 
drug trial exit 
(n =59) 
Standard care 
following drug trial 
(n =58)  
Not randomised 
(n =12): 
Refused  (n =12) 
Randomised 
(n =117) 
Received nurse-
managed care and data 
available at time one 
(n =46) 
Did not receive nurse-managed 
care and data unavailable at time 
one (n =13): 
Died (n = 4) 
Too ill (n = 2) 
 Refused  (n =4) 
Remained on drug trial (n =2) 
 Data  incomplete  (n =1) 
Data collected within 
7 days of drug trial 
(n =49) 
Data unavailable at timeone 
(n =9): 
Died (n = 1) 
 Too  ill  (n =5) 
 Refused  (n =1) 
Remained on drug trial (n =1) 
Data incomplete (n =1)
Data available at time 
two  
(n =27) 
Data unavailable at time 
two (n =19): 
Unable to contact (n =6) 
Died (n = 3) 
Too ill (n = 10)
Data available at time 
two 
(n =37) 
Data unavailable at time 
two (n =12): 
Unable to contact (n =8) 
Died (n = 2) 
Too ill (n = 2)
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
Figure 1 Flow of participants through trial.
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shave had all the feedback that I need about the trial I took part in
(Po0.01) and I feel I know how I will be followed up now I am no
longer in the trial (P¼0.02) with those in the intervention group
indicating significantly higher levels of agreement with the
statements. Interestingly, both groups felt that they had con-
tributed to cancer research by taking part in the trial with no
difference between the groups (P¼0.11).
Satisfaction with the intervention
A total of 44 respondents in the intervention group (from a
possible 47) completed the MISS. Satisfaction with all elements
(cognitive, emotional and behavioural) of the trial exit interview
was good. Overall patient satisfaction with the intervention was
high (median score¼4.5 where 5 is greatest satisfaction).
DISCUSSION
An individuals desire for ‘feedback’ and the provision of
information about how the trial is going can be seen in
the context of the process of adaptation within the context of
life threatening situations (Turnquist et al, 1988), a kind of
‘search for meaning’. Research in this area suggests that an
individual’s ability to search for and find a meaning in their illness
and treatment may have a significant impact on psychosocial
well-being and adjustment to the impact of cancer on their lives
(Lewis, 1989; Luker et al, 1996). Providing feedback and
information about the trial, an individual has participated
in may be one way that on-going psychosocial support for
patients can be offered and the contribution made through
their trial participation acknowledged. This requirement is
even more important in this particular group of patients who
are at the end of their disease trajectory, have a limited life
Table 1 Demographic factors, tumour and clinical trial type by study
group
Intervention
group (n¼59)
Control
group (n¼58)
Gender
Male:female 1.1:1 1.4:1
Age in years
Mean (s.d.) 59.8 (11.6) 57.4 (10.8)
Marital status n (%)
Living with spouse/partner 53 (89.8) 45 (81.8)
Divorced 3 (5.1) 3 (5.5)
Widowed 1 (1.7) 4 (7.3)
Single 2 (3.4) 3 (5.5)
Missing 3
Tumour type n (%)
Breast 7 (12.1%) 5 (8.6%)
Lung 8 (13.8%) 7 (12.1%)
Upper GI 7 (12.1%) 10 (17.2%)
Ovary 7 (12.1%) 5 (8.6%)
Colorectal 11 (19.0%) 11 (19.0%)
Other 18 (31.0%) 20 (34.5%)
Drug Trial centre n (%)
Centre 1 52 (88.1%) 51 (87.9%)
Centre 2 7 (11.9%) 7 (12.1)
Completed drug trial n (%)
Yes 17 (28.8%) 20 (34.5%)
No 42 (71.2%) 38 (65.5%)
Days spent on drug trial
Mean (s.d.) 96.8 (68.2) 97.8 (54.0)
Table 2 Anxiety, Depression Physical Distress and Psychological Distress scores within 7 days of trial exit and after 4–6 weeks
Intervention mean (s.d.) Control mean (s.d.) P-value
a
HADS Anxiety Scores Within 7 days 4.7 (4.2) (n¼46) 4.8 (3.9) (n¼49)
4–6 weeks 3.6 (3.8) (n¼27) 4.4 (3.7) (n¼37)
Change over time  1.2 (3.6) (n¼27)  0.6 (2.7) (n¼37) 0.27
HADS Depression Scores Within 7 days 5.2 (4.3) (n¼46) 4.9 (3.3) (n¼49)
4–6 weeks 5.3 (5.0) (n¼27) 4.7 (3.8) (n¼37)
Change over time 0.2 (2.7) (n¼27)  0.2 (3.3) (n¼27) 0.51
RSCL Physical Distress Scores Within 7 days 23.8 (13.8) (n¼46) 20.4 (10.5) (n¼49)
4–6 weeks 20.4 (14.7) (n¼27) 18.9 (13.3) (n¼37)
Change over time  2.6 (13.8) (n¼27) –2.2 (14.0) (n¼37) 0.73
RSCL Psychological Distress Scores Within 7 days 21.8 (24.0) (n¼46) 23.4 (18.9) (n¼49)
4–6 weeks 18.9 (20.3) (n¼27) 23.0 (20.4) (n¼37)
Change over time  2.3 (20.4) (n¼27)  2.3 (18.4) (n¼37) 0.49
aBetween groups, Mann–Whitney U test.
Table 3 Views on information needs and perception of contribution by study group (scores out of five, higher scores indicate greater agreement)
Intervention
group (n¼46) median (IQR)
Control
group (n¼49) median (IQR) P-value
a
I have contributed to cancer research 5 (5,5) 5 (5,5) 0.11
I know how the trial is currently going 5 (3.75,5) 1 (1,4) o0.0005
I know how other people on the trial are doing 4 (1,5) 1 (1,4) 0.001
I have had all the feedback that I need about the trial I took part in 5 (4,5) 4 (1,5) 0.009
I know how I will be followed up now I am no longer in the trial 5 (5,5) 5 (1,5) 0.022
aMann–Whitney U test.
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sexpectancy, have complex needs and who are participating in
a drug trial that is unlikely to have any therapeutic benefit
(Estey et al, 1986; Marsoni et al, 1987; Decoster et al, 1990). With
this underpinning rationale we designed an intervention to
meet these needs. The findings show that nurse-managed trial
conclusion meets patients’ information needs at trial conclusion.
The intervention was acceptable to patients and this study
supports previous work in relation to the acceptability of
nurse-managed follow-up and satisfaction with this kind of
care delivery (Moore et al, 2002). It would appear that, while
there was no significant difference between the intervention and
control group in terms of anxiety and depression levels at base
line and follow-up, anxiety was reducing over time for those
individuals in the intervention arm of the study but this requires
further testing. Overall, the intervention was effective in providing
patients with information and feedback about the trial that
had been identified as a specific need at trial conclusion in our
earlier work.
One key limitation of this study is the lack of power as a result of
the high attrition between the two time points. This was perhaps
inevitable due the high mortality rate associated with this group of
patients. It may also be a reflection of an overestimation of the
effect of the intervention in our initial sample size calculations. A
further limitation relates to the mode of completion of the
questionnaires. Patients completing their questionnaires with the
help of a researcher may provide different responses to those who
complete alone.
CONCLUSIONS
Providing structured support and information at the end of a trial
ensures information needs are met and is acceptable to patients.
The trial conclusion strategy outlined here would therefore appear
to be a simple and effective way to provide on-going psychosocial
support to patients once the trial has completed. It can bridge the
gap between the end of the trial and the next follow-up
appointment and make a difference to the trial conclusion
experience of vulnerable patients.
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